Research programme: protease activated cancer therapy - Dendreon

Drug Profile

Research programme: protease activated cancer therapy - Dendreon

Alternative Names: CVS 10290; PACT; Research programme: protease activated cancer therapy - Corvas

Latest Information Update: 16 May 2007

Price : *
* Final gross price and currency may vary according to local VAT and billing address.

At a glance

  • Originator Dendreon Corporation
  • Class
  • Mechanism of Action Protease stimulants
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    No

Highest Development Phases

  • Discontinued Cancer

Most Recent Events

  • 05 Jan 2004 The activities of Dendreon San Diego LLC are being relocated to Dendreon's Seattle headquarters
  • 04 Aug 2003 Corvas International has been acquired by Dendreon Corporation and is now called Dendreon San Diego LLC
  • 22 Jul 2003 Data presented at the 94th Annual Meeting of the American Association for Cancer Research (AACR-2003) have been added to the Cancer pharmacodynamics section
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top